Immunic closes $200M private placement; CEO Vitt to transition; Phase 3 MS data by end-2026

IMMUNIC, INC.

Closed oversubscribed private placement of up to $400M; $200M gross proceeds received Feb 17, 2026.
Net proceeds ~$187M expected to fund operations into late 2027, including Phase 3 ENSURE trials and NDA submission mid-2027.
CEO Daniel Vitt to transition to senior scientific role; search for new CEO with commercial MS expertise underway.
Simona Skerjanec appointed Interim Chairperson; Thor Nagel (BVF Partners) named to Board.
Net loss for FY2025 was $97.2M ($0.62/share); cash $15.5M at Dec 31, 2025, plus placement proceeds.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.